COGT · Cogent Biosciences Inc
United States · RS rating 22 · As of 2026-10-14
| Price | 28.15 USD |
|---|---|
| 1-day change | +0.2% |
| RS rating (overall / 1M / 3M / 12M) | 22 / 17 / 14 / 93 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 31 / 15 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -10.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +34.3% |
| Market cap (USD) | $5.9B |